spacer
home > ebr > spring 2004 > new trends in dermatology clinical research
PUBLICATIONS
European Biopharmaceutical Review

New Trends in Dermatology Clinical Research

In dermatology it is often possible to establish clinical efficacy before committing to a full clinical and safety programme. This is because the focus of dermatology - the skin - is directly accessible for therapy. In contrast to systemic or topical application to large areas, in many cases a very small treatment area can be selected for dosing of topical therapies, effectively eliminating risks associated with systemic exposure.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Betsy Hughes-Formella, Managing Director at Bioskin GmbH

Dr Betsy Hughes-Formella received her PhD in Physiology from the University of Georgia in Athens, Georgia in 1983. She moved to Germany to join a research team at the University Medical Center in Hamburg. Her research interests were in the area of steroid receptors in the neuromuscular system and later in the pathogenesis of melanoma. In 1992 Dr Hughes joined Bioskin GmbH as Managing Director. In her current capacity she consultants and advises on clinical development concepts and study designs for Bioskin sponsors. In addition, she is responsible for the co-ordination of the company's business development and strategic alliance opportunities. She is an active member of several scientific societies, including a position on the board of regents of the German Association of Applied Human Pharmacology (AGAH) and the working group for dermocosmetics in the German Association for Dermopharmacie (GD).

spacer
Dr Betsy Hughes-Formella
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cytel expansion unlocks innovative clinical development expertise for APAC biopharma sector

Waltham, MA, September 06, 2022 – Cytel Inc., a pioneer of adaptive clinical trial design and provider of advanced biometrics services, has expanded its operations into the Asia-Pacific region (APAC). This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions. For more than 35 years, Cytel has pioneered innovative adaptive clinical trial designs and a suite of validated statistical and predictive software platforms. Cytel has also successfully supported sponsors in all aspects of innovative clinical trials, from statistical design to implementation and regulatory acceptance, helping them reduce costs, shorten timelines, and better unlock the value of their data.
More info >>

White Papers

Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles

NanoSight

The study of exosomes and other cell-derived microvesicles is an area of rapidly growing importance and the subject of intense interest and research. The previous lack of suitable methods for their detection, analysis, enumeration and phenotyping is proving to be a significant limitation in these studies. This mini-review shows the degree to which the technique of Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement